CN115916342A - 用于治疗纤维化疾病和癌症的化合物、组合物和方法 - Google Patents

用于治疗纤维化疾病和癌症的化合物、组合物和方法 Download PDF

Info

Publication number
CN115916342A
CN115916342A CN202180051458.8A CN202180051458A CN115916342A CN 115916342 A CN115916342 A CN 115916342A CN 202180051458 A CN202180051458 A CN 202180051458A CN 115916342 A CN115916342 A CN 115916342A
Authority
CN
China
Prior art keywords
compound
alkyl
optionally substituted
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180051458.8A
Other languages
English (en)
Chinese (zh)
Inventor
P·S·洛
J·V·拿破仑
F·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of CN115916342A publication Critical patent/CN115916342A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202180051458.8A 2020-07-08 2021-07-07 用于治疗纤维化疾病和癌症的化合物、组合物和方法 Pending CN115916342A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063049556P 2020-07-08 2020-07-08
US63/049,556 2020-07-08
PCT/US2021/040736 WO2022011043A2 (en) 2020-07-08 2021-07-07 Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer

Publications (1)

Publication Number Publication Date
CN115916342A true CN115916342A (zh) 2023-04-04

Family

ID=79553738

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180051458.8A Pending CN115916342A (zh) 2020-07-08 2021-07-07 用于治疗纤维化疾病和癌症的化合物、组合物和方法

Country Status (7)

Country Link
US (1) US20230248835A1 (https=)
EP (1) EP4178574A4 (https=)
JP (1) JP2023533961A (https=)
CN (1) CN115916342A (https=)
AU (1) AU2021305193A1 (https=)
CA (1) CA3184740A1 (https=)
WO (1) WO2022011043A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119215159A (zh) * 2024-09-24 2024-12-31 深圳市格茵莱生物科技有限公司 树突状细胞多抗原负载免疫治疗方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3996715A4 (en) * 2019-07-08 2024-01-03 Purdue Research Foundation COMPOUNDS AND METHODS FOR TREATING AND PREVENTING FIBROTIC DISEASES AND CANCER
EP4271378A4 (en) * 2021-01-04 2026-03-11 Purdue Research Foundation METHODS FOR IMPROVING MODIFIED CELL THERAPIES IN CANCER TREATMENT
EP4683669A2 (en) * 2023-03-23 2026-01-28 Purdue Research Foundation Combinations and methods for enhancing checkpoint inhibitor therapies in cancer treatment

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051317A2 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2005066169A2 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
WO2005094531A2 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2006098852A2 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
WO2008135791A1 (en) * 2007-05-08 2008-11-13 Astrazeneca Ab Imidazoquinolines with immuno-modulating properties
WO2017040233A1 (en) * 2015-08-31 2017-03-09 3M Innovative Properties Company GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS
WO2019048353A1 (en) * 2017-09-06 2019-03-14 Biontech Ag SUBSTITUTED IMIDAZOQUINOLINES AS TLR7 AGONISTS
WO2020139618A1 (en) * 2018-12-26 2020-07-02 Birdie Biopharmaceuticals, Inc. Immune modulatory combinations and methods for treating cancers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413558A (pt) * 2003-08-12 2006-10-17 3M Innovative Properties Co compostos contendo imidazo substituìdo por hidroxilamina
JP2007530579A (ja) * 2004-06-10 2007-11-01 スリーエム イノベイティブ プロパティズ カンパニー アミド置換イミダゾピリジン、イミダゾキノリン、およびイミダゾナフチリジン
DE212016000029U1 (de) * 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
AU2017271550B2 (en) * 2016-05-25 2023-11-02 Endocyte, Inc. Method of treating cancer by targeting myeloid-derived suppressor cells
WO2020023680A1 (en) * 2018-07-24 2020-01-30 Torque Therapeutics, Inc. Tlr7/8 agonists and liposome compositions
AU2019335366A1 (en) * 2018-09-07 2021-03-25 Birdie Biopharmaceuticals, Inc. Imidazoquinoline compounds and uses thereof
WO2020236253A1 (en) * 2019-05-20 2020-11-26 Massachusetts Institute Of Technology Boronic ester prodrugs and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051317A2 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2005066169A2 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
WO2005094531A2 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2006098852A2 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
WO2008135791A1 (en) * 2007-05-08 2008-11-13 Astrazeneca Ab Imidazoquinolines with immuno-modulating properties
WO2017040233A1 (en) * 2015-08-31 2017-03-09 3M Innovative Properties Company GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS
WO2019048353A1 (en) * 2017-09-06 2019-03-14 Biontech Ag SUBSTITUTED IMIDAZOQUINOLINES AS TLR7 AGONISTS
WO2020139618A1 (en) * 2018-12-26 2020-07-02 Birdie Biopharmaceuticals, Inc. Immune modulatory combinations and methods for treating cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER B. RODELL，等: "TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy", NATURE BIOMEDICAL ENGINEERING, vol. 2, no. 08, 21 May 2018 (2018-05-21), pages 580 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119215159A (zh) * 2024-09-24 2024-12-31 深圳市格茵莱生物科技有限公司 树突状细胞多抗原负载免疫治疗方法

Also Published As

Publication number Publication date
WO2022011043A3 (en) 2022-03-03
WO2022011043A2 (en) 2022-01-13
EP4178574A2 (en) 2023-05-17
JP2023533961A (ja) 2023-08-07
EP4178574A4 (en) 2024-04-10
AU2021305193A1 (en) 2023-02-09
CA3184740A1 (en) 2022-01-13
US20230248835A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
CN115916342A (zh) 用于治疗纤维化疾病和癌症的化合物、组合物和方法
CN115192577B (zh) Kras突变蛋白抑制剂
CA2653941C (en) Substituted amino purine derivatives and uses thereof
EP2809660B1 (en) Macrocyclic compounds for modulating il-17
US9446040B2 (en) Substituted imidazoquinolines
JP2024520283A (ja) 化学的カップリングリンカー及びその使用
ES3060380T3 (en) Immunomodulator
CA3134765A1 (en) Bi-functional molecules to degrade circulating proteins
WO2020028608A1 (en) 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR
CN113195469B (zh) 含氮并环化合物、其制备方法及用途
CN112654622B (zh) 并环化合物、其制备方法及用途
WO2022247909A1 (zh) 愈创木烷类倍半萜衍生物及其制药用途
CN104987504A (zh) 聚乙二醇化拉帕替尼及其注射剂和制备方法
AU2024226021A1 (en) Camptothecin derivative, conjugate thereof, preparation method therefor and medical use thereof
CN119604504A (zh) 一类双并环化合物、其制备方法及用途
WO2022156678A1 (zh) 大环tlr7激动剂、其制备方法、药物组合物及其用途
AU2023403996A1 (en) Compound usable in conjugation reaction and conjugate thereof
CN121449666A (zh) Sting促效剂
CN114599360A (zh) 4-氨基-咪唑并喹啉化合物及其用途
CN116406301B (zh) 可用于治疗癌症的sn38肽缀合物
TW202521540A (zh) 咪唑并[4,5-d]嗒𠯤化合物及其接合物、其製備、及其治療應用
CN114555565A (zh) 含氮并环化合物、其制备方法及用途
EP4674840A1 (en) Chemical coupling linker and use thereof
CN115244045A (zh) 抑制半乳凝素-3的c-糖苷酮、醚和醇
WO2008034920A1 (es) Método de extracción de sustancias de la planta ceropegia fusca con anticidad antineoplásica y composiciones farmacéuticas que las contienen.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination